🔎 Trials Near Me

Pradžia › Wilmo navikas › Tennessee

Wilmo navikas klinikiniai tyrimai Tennessee

6 tyrimai dėl Wilmo navikas ieško dalyvių vietose Tennessee.

Miestai Tennessee

Oficialus tyrimo tekstas (anglų kalba)

Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

  • Saint Jude Children's Research Hospital, Memphis
Renkami dalyviai2 fazė
Amžius nuo 12 iki 39 · Visoms lytims · Atnaujinta 2026-09-29 · NCT04616560

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

  • East Tennessee Childrens Hospital, Knoxville
  • Saint Jude Children's Research Hospital, Memphis
  • The Children's Hospital at TriStar Centennial, Nashville
  • ir dar 1
Renkami dalyviai2 fazė
Iki 30 metų · Visoms lytims · Atnaujinta 2026-08-25 · NCT04322318

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Saint Jude Children's Research Hospital, Memphis
Renkami dalyviai1/2 fazė
12 Months – 30 Years · Visoms lytims · Atnaujinta 2026-08-25 · NCT04851119

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

  • St. Jude Children's Research Hospital, Memphis
Renkami dalyviai1 fazė
Iki 21 metų · Visoms lytims · Atnaujinta 2026-05-19 · NCT04897321

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

  • St. Jude Children's Research Hospital, Memphis
Renkami dalyviai1/2 fazė
12 Months – 30 Years · Visoms lytims · Atnaujinta 2026-05-19 · NCT04901702

Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation

  • St.Jude Children's Research Hospital, Memphis
Renkami dalyviai2 fazė
Visi amžiai · Visoms lytims · Atnaujinta 2026-04-23 · NCT04968990

Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.